Clinical experience with gemcitabine in pancreatic carcinoma

ONCOLOGY

Volumn 11, Issue 11, 1997, Pages 1615-1622

  Michael, Michael ^a   Moore, Malcolm ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOMYCIN C; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SEMUSTINE; STREPTOZOCIN; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; FEVER; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; DEOXYCYTIDINE; DRUG EVALUATION; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030716753     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Cancer Facts & Figures - 1997. Atlanta, American Cancer Society, 1997.
2. Casper ES: Pancreatic cancer: How can we progress? Ear J Cancer 29A: 171-172, 1993.
3. Moore M: A review of the role of chemotherapy in the management of advanced pancreatic cancer. Curr Oncol 1:212-216, 1994.
4. Schnall SF, Macdonald JS: Chemotherapy for adenocarcinoma of the pancreas. Semin Oncol 23:220-228, 1996.
5. Carter SK, Comis RL: The integration of a combined modality approach for cancer treatment: VI. Pancreatic adenocarcinoma. Cancer Treat Rev 2:193-214, 1975.
6. Moertel CG: Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 5:777-793, 1976.
7. Cullinan SA, Moertel CO, Fleming TR, et al: A comparison of chemotherapeutic regimens in the treatment of advanced pancreatic and gastric cancer. JAMA 253:2061-2067, 1985.
8. Cullinan S, Moertel CG, Wieand HS, et al: A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 65:2207-2212, 1990.
9. Crown J, Casper ES, Botet J, et al: Lack of efficacy of high-dose leucovorin and fluorou- racil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 9:1682-1686, 1991.
10. Cascinu S, Fedeli A, Fedeli SL, et al: 5-Fluorouracil, leucovorin and Interferon alpha 2b in advanced pancreatic cancer: A pilot study. Ann Oncol 4:83-84, 1993.
11. Brennan MF, Kinsella TJ, Casper ES: Cancer of the Pancreas, in Devita VT, Helman S, Rosenberg SA, (eds): Cancer: Principles & Practice of Oncology, 4th ed, pp 849-882. Philadelphia, JB Lippincoti, 1993.
12. Bukowski RM, Balcerzak SP, O'Bryan RM, et al: Randomized trial of FUra and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Cancer 52:1577-1582, 1983
13. Oster MW, Gray R, Panasci L, et al Chemotherapy for advanced pancreatic cancer: A comparison of FAM with FSM. Cancer 57:29-34, 1986.
14. The Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycm-C plus fluorouracil. J Clin Oncol 4:1794-1798, 1986.
15. Kelsen D, Hudis C, Niedzwiecki D, et al: A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68:965-969, 1991.
16. Horton J, Gelber R, Engstrom P, et al: Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treat Rep 65:65-68, 1981.
17. Frey C, Twomey P, Keehn R, et al: Randomized study of 5-FU and CCNU in pancreatic cancer: Report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 47:27-31, 1981.
18. Rothenberg ML, Abbruzzese JL, Moore M, et al: A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78:627-632, 1996.
19. Moore M: Activity of gemcitabine in patients with advanced pancreatic carcinoma. Cancer 78:633-638, 1996.
20. Taylor OM, Benson EA, McMahon MJ, et ah Clinical trial of tamoxifen in patients with irrresectable pancreatic adenocarcinoma: The Yorkshire Gastrointestinal Tumour Group. Br J Surg 80:384-386, 1993.
21. Moore M, Andersen J, Burris H, et al. A randomized phase III trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer (abstract). Proc Am Soc Clin Oncol 14:199, 1995
22. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353, 1996.
23. Plunkett W, Huang P, Xu Y-Z et al: Gemcitabine: Metabolism, mechanism of action and self-potentiation. Semin Oncol 22(suppl 4):3-10, 1995.
24. Hertel, LS, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422, 1990.
25. Gandhi V, Huang P, Xu Y-Z, et al: Metabolism and action of 2′,2′-difluorodeoxycytidine: Self potentiation of cytotoxcity. Adv Exp Med Biol 309A: 125-130, 1991.
26. Heinemann V, Hertel LW, Grindey GB, et al: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-b-D-arabinofurartosylcytosine. Cancer Res 48:4024-4031, 1988.
27. Shewach DS, Reynolds KK, Hertel L: Nucleotide specificity of human deoxycytidine kinase. Molec Pharmacol 42:518-524, 1992.
28. Gandhi V, Plunkett W: Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosylnucleosides. Cancer Res 50:3675-3680, 1990.
29. Santini V, D'Ippolito G, Bernabei PA, et al: Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL60: Direct comparison of cytotoxicity and cellular ara-C uptake enhancement. Leak Res 20:37-45, 1996.
30. Plunkett W, Ghandi V, Chubb S, et al: 2',2'-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleoside Nucleotide 8:775-785, 1989.
31. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991.
32. Heinemann V, Xu Y-Z, Chubb S, et al: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res 52:533-539, 1992.
33. Huang P, Chubb S, Hertel LW, et al: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991.
34. Huang P, Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncology 22(suppl 11): 19-25, 1995.
35. Heinemaim V, Xu Y-Z, Chubb S, et al: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567-572, 1990.
36. Heinemann V, Schulz L, Issels RD, et al: Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22(suppl 11):11-18, 1995.
37. O'Rourke TJ, Brown TD, Havlin K, et al: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30A:417-418, 1994.
38. Popllin EAD, Corbett T, Flaherty L, et al: Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study Invest New Drugs 10:165-170, 1992.
39. Anderson H, Thatcher N, Walling S, et al: A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74:460-462, 1996.
40. Clavel M, Guastella J, Peters G: Phase I study of LY 188011, 2′,2′ difluorodeoxycytidine. Invest New Drugs 7:379, 1989.
41. Anderson H, Lund B, Thatcher N, et al: Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994.
42. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994.
43. Carmichael J, Possinger K, Philip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995.
44. Moore MJ, Tannock I, Ernst S, et al: Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transi- tional cell carcinoma (abstract). Proc Am Soc Clin Oncol 15:250, 1995.
45. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. Ann Oncol 5:283-285, 1994.
46. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994.
47. Carmichael J, Fink U, Russell RCG, et al: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73:101-105, 1996.
48. Andersen JS, Burris HA, Casper E, et al: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer (abstract). P roc Am Soc Clin Oncol 13:461, 1994.
49. Storniolo AM, Enas NH, Brown CA, et al. Treatment investigational new drug program for Gemzar (gemcitabine HCl) in patients with pancreas cancer (Abstract 1088). Proc Am Soc Clin Oncol 16:306, 1997.
50. Lawrence TS, Chang EY, Hahn TM, et al: Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867-872, 1996.